BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 1,177 Shares

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 1,177 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $266.40, for a total value of $313,552.80. Following the transaction, the insider now directly owns 470 shares in the company, valued at $125,208. The trade was a 71.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Lai Wang also recently made the following trade(s):

• On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The stock was sold at an average price of $251.37, for a total transaction of $118,143.90.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total transaction of $353,850.78.

BeOne Medicines Price Performance

ONC traded down $5.70 during trading on Friday, hitting $247.08. 230,772 shares of the stock traded hands, compared to its average volume of 298,435. The company has a market cap of $27.07 billion, a price-to-earnings ratio of -66.42 and a beta of 0.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. The company has a 50-day moving average price of $245.59. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $141.31 and a 12-month high of $287.88.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. As a group, equities analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the company. Sanford C. Bernstein set a $259.00 price objective on BeOne Medicines in a research note on Thursday, March 13th. TD Securities reiterated a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a report on Thursday, April 24th. Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Bank of America upgraded shares of BeOne Medicines from a "neutral" rating to a "buy" rating and increased their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, Macquarie increased their price target on BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.